Aspirin for prevention of stroke in atrial fibrillation [1]

Stroke

Volumn 37, Issue 7, 2006, Pages 1640-

  Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

BLEEDING; CLINICAL TRIAL; DRUG ELUTING STENT; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; STROKE; VASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; NOTE; THROMBOPHILIA; TREATMENT FAILURE;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOPHILIA; TREATMENT FAILURE; WARFARIN;

EID: 33745960482     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000227301.55019.60     Document Type: Letter

References (8)

1. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M. Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447-451.
2. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2005.
3. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;4:CD001925.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
5. Choudhury A, Lip GYH. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33:282-289.
6. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M. AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:650-656.
7. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337-1343.
8. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart. 2006;92:155-161.